2022/05/12 更新

写真a

シミズ ダイ
清水 大
SHIMIZU Dai
所属
医学部附属病院 消化器外科二 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 博士(医学) ( 2016年3月   名古屋大学 ) 

 

論文 77

  1. Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer.

    Sakata K, Kanda M, Shimizu D, Nakamura S, Inokawa Y, Hattori N, Hayashi M, Tanaka C, Nakayama G, Kodera Y

    International journal of oncology   60 巻 ( 6 )   2022年6月

     詳細を見る

    記述言語:英語   出版者・発行元:International journal of oncology  

    To improve the outcome of gastric cancer, novel markers that predict postoperative prognosis are required. For this purpose, the function of cellular retinoic acid binding protein 1 (CRABP1) in gastric cancer cells was investigated and it was determined whether it serves as a novel biomarker for gastric cancer. Reverse transcription‑quantitative (RT‑q)PCR and a PCR‑array method were used to determine whether the expression of CRABP1 mRNA in gastric cancer cell lines correlated with the expression of cancer‑related genes. The correlations of CRABP1 mRNA expression in tissues with clinicopathological factors of 230 patients who underwent radical gastrectomy were further evaluated. CRABP1 mRNA levels varied among gastric cancer cell lines and showed significant positive correlations with numerous epithelial‑mesenchymal transition factors. Additionally, CRABP1 knockdown significantly suppressed the proliferation, migration and invasion of gastric cancer cell lines. In a mouse xenograft model of peritoneal metastasis of gastric cancer, it was found that the total weight of disseminated nodules was lower in the group, in which CRABP1 mRNA levels were knocked down compared with those of the untransfected group. Disease‑free survival (DFS) was significantly shorter in patients with high expression of CRABP1, and multivariate analysis of DFS revealed that high expression of CRABP1 in the tumor area and lymph node metastasis served as an independent factor associated with poor prognosis. High expression of CRABP1 in cancer tissues was associated with a greater incidence of peritoneal recurrences after curative gastrectomy. These findings indicated that CRABP1 contributes to the malignant phenotype of gastric cancer cells and may serve as a biomarker for prognosing recurrence after curative resection, particularly peritoneal dissemination.

    DOI: 10.3892/ijo.2022.5353

    Scopus

    PubMed

  2. Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells

    Umeda Shinichi, Kanda Mitsuro, Shimizu Dai, Nakamura Shunsuke, Sawaki Koichi, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Nakayama Goro, Kodera Yasuhiro

    GASTRIC CANCER   25 巻 ( 3 ) 頁: 558 - 572   2022年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:Gastric Cancer  

    Background: Metastatic gastric cancer (GC) has a poor prognosis, and elucidating the molecular mechanisms involved in metastasis may lead to the development of novel therapeutic modalities. Methods: Transcriptome analysis of surgically resected metastatic tissue from GC patients and noncancerous tissue was performed to identify novel metastasis-related genes. Analyses of in vitro cell function, apoptosis, the cell cycle and cancer stemness were performed using GC cell lines with a stable knockout of a candidate gene. In vivo percutaneous, peritoneal dissemination and liver metastasis xenograft models were also generated. PCR array and proteome analyses were performed. Expression of the candidate gene was analyzed in GC tissues from 300 patients. Results: Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) was upregulated in the metastatic tissues. LAMP5 knockout significantly suppressed proliferation, invasion, and migration of GC cells and increased apoptosis, cell cycle arrest and cancer stemness. LAMP5 knockout virtually suppressed tumor growth in in vivo percutaneous, peritoneal dissemination and liver metastasis models. EMT- and autophagy-related genes were associated with LAMP5. High LAMP5 mRNA levels were significantly associated with a worse prognosis. Conclusion: LAMP5 plays a vital role in metastasis formation and may be a promising novel target of drug development for metastatic GC in the future.

    DOI: 10.1007/s10120-022-01284-y

    Web of Science

    Scopus

    PubMed

  3. ASO Visual Abstract: Prognostic Value of a Modified Albumin-Bilirubin Grade Designed for Patients with Esophageal Squamous Cell Carcinoma after Radical Resection.

    Shinozuka T, Kanda M, Shimizu D, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Koike M, Kodera Y

    Annals of surgical oncology     2022年4月

     詳細を見る

    記述言語:英語  

    DOI: 10.1245/s10434-022-11784-x

    PubMed

  4. Prognostic Value of a Modified Albumin-Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection

    Shinozuka Takahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Chie, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Koike Masahiko, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY     2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Annals of Surgical Oncology  

    Background: The albumin–bilirubin (ALBI) score was originally developed to assess the severity of liver dysfunction in patients with hepatocellular carcinoma and has subsequently been used as a prognostic marker for that disease. Here, we examined the value of the preoperative ALBI score as a prognostic marker for patients with esophageal squamous cell carcinoma (ESCC) after radical esophagectomy. Methods: We retrospectively analyzed data from 449 patients who underwent curative resection for ESCC. The ALBI score was calculated as (log10 serum bilirubin [μmol/l] × 0.66) + (serum albumin [g/l] × − 0.0852). Receiver operating characteristic curve analysis was used to define a preoperative modified ALBI (mALBI) score for patient stratification. Results: Of the 449 ESCC patients, 232 and 217 were assigned to mALBI Grade 1 or Grade 2 groups based on preoperative ALBI scores of ≤ − 3.33 or > − 3.33, respectively. Preoperative mALBI grade was significantly associated with age, excessive alcohol consumption, squamous cell carcinoma antigen level, and clinical disease stage. The mALBI Grade 2 group had significantly shorter disease-specific and recurrence-free survival than the mALBI Grade 1 group. Multivariate analysis demonstrated that mALBI Grade 2 was an independent prognostic factor for disease-specific survival (hazard ratio 1.86, 95% confidence interval 1.18–2.93, P = 0.0074). In most subgroup analyses, mALBI Grade 2 was associated with a greater risk of disease-specific death. Conclusions: mALBI grade serves as a simple and useful prognostic marker for disease-specific survival in patients with ESCC after radical esophagectomy.

    DOI: 10.1245/s10434-022-11654-6

    Web of Science

    Scopus

    PubMed

  5. SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma

    Baba Hayato, Kanda Mitsuro, Sawaki Koichi, Nakamura Shunsuke, Ueda Sei, Shimizu Dai, Koike Masahiko, Kodera Yasuhiro, Fujii Tsutomu

    ANNALS OF SURGICAL ONCOLOGY   29 巻 ( 4 ) 頁: 2699 - 2709   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Annals of Surgical Oncology  

    Background: The expression of solute carrier (SLC) 7 family genes is reportedly associated with several malignancies. Here, we focused on SLC7A9 and investigated its expression, function, and clinical significance in esophageal squamous cell carcinoma (ESCC). Methods: SLC7A9 transcription levels were evaluated in 13 ESCC cell lines, and polymerase chain reaction (PCR) array analysis was conducted to detect coordinately expressed genes with SLC7A9. SLC7A9 contributions to proliferation, invasion, and migration were evaluated in ESCC cells subjected to siRNA-mediated gene knockdown and pCMV6-entry plasmid-mediated overexpression. SLC7A9 expression was detected in 189 ESCC tissues by quantitative reverse-transcription (qRT)-PCR and correlated with clinicopathological parameters. Results: The expression levels of SLC7A9 varied widely in ESCC cell lines and correlated with FGFBP1 expression. Knockdown of SLC7A9 significantly suppressed the proliferation, invasion, and migration of the ESCC cell lines. Moreover, overexpression of SLC7A9 enhanced cell proliferation and migration. In analyses of clinical specimens, SLC7A9 mRNA was overexpressed in the ESCC tissues compared with the adjacent normal esophageal tissues. High mRNA expression was significantly associated with high levels of squamous cell carcinoma-related antigen and carcinoembryonic antigen, advanced disease stage, and lymph node metastasis. High SLC7A9 expression was also significantly associated with poor disease-specific and disease-free survival, and lymph node recurrence after radical surgery, but not with the other recurrence patterns. On multivariate analysis, high SLC7A9 expression was an independent predictor of lymph node recurrence. Conclusions: SLC7A9 influences the malignant behavior of ESCC cells. Tumor SLC7A9 expression may serve as a novel biomarker for predicting lymph node metastasis and recurrence in ESCC patients.

    DOI: 10.1245/s10434-021-11001-1

    Web of Science

    Scopus

    PubMed

  6. ASO Visual Abstract: SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma

    Baba Hayato, Kanda Mitsuro, Sawaki Koichi, Nakamura Shunsuke, Ueda Sei, Shimizu Dai, Koike Masahiko, Kodera Yasuhiro, Fujii Tsutomu

    ANNALS OF SURGICAL ONCOLOGY   29 巻 ( 4 ) 頁: 2710 - 2710   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Annals of surgical oncology  

    DOI: 10.1245/s10434-021-11065-z

    Web of Science

    Scopus

    PubMed

  7. Drain Amylase Concentrations at 3 h After Gastrectomy Enhance Early Prediction of Postoperative Peripancreatic Inflammatory Fluid Collection

    Nakanishi Koki, Kanda Mitsuro, Tanaka Chie, Takeda Shigeomi, Tanaka Katsuhito, Shimizu Dai, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Nakayama Goro, Fujiwara Michitaka, Kodera Yasuhiro

    WORLD JOURNAL OF SURGERY   46 巻 ( 3 ) 頁: 648 - 655   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:World Journal of Surgery  

    Background: Despite numerous studies of peripancreatic inflammatory fluid collection (PIFC) that report on the relevance of the drain amylase concentration (D-AMY), early prediction using this assay is problematic. This study aimed to investigate the clinical significance of measuring the D-AMY at 3 h after gastrectomy (POD0) for gastric cancer. Methods: This retrospective analysis included consecutive patients who underwent gastrectomy combined with peripancreatic lymph node dissection. The predictive value of D-AMY on POD0 and postoperative day 1 (POD1) for clinically relevant PIFC was evaluated together or individually. Results: Analyses were performed in 204 patients. Twenty (9.8%) patients experienced PIFC. D-AMY cutoffs of 721 IU/L on POD0 and 1695 IU/L on POD1 were determined using the receiver operating characteristic curve analysis for predicting PIFC. The D-AMY on POD0 had higher sensitivity (80%) but lower specificity (66.3%) for prediction of PIFC, compared with those of D-AMY on POD1 (65%, 89.1%, respectively). When combination marker analysis was performed, the highest risk group (D-AMY ≥ the cutoff values of POD0 and POD1) were associated with an elevated rate of occurrence (44%) and a high positive likelihood ratio (7.36) compared with those of the single cutoff group. The lowest risk group (D-AMY < the cutoff values on POD0 and POD1) was associated with a low rate of occurrence (2.5%) and low negative likelihood ratio (0.24) compared with those of the single cutoff group. Conclusions: Combined measurements of D-AMYs on POD0 and POD1 enhanced early prediction of PIFC after gastrectomy.

    DOI: 10.1007/s00268-021-06401-z

    Web of Science

    Scopus

    PubMed

  8. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

    Kanda Mitsuro, Shimizu Dai, Miyata Kazushi, Maeda Osamu, Tanaka Chie, Inokawa Yoshikuni, Hattori Norofumi, Hayashi Masamichi, Ando Masahiko, Kuwatsuka Yachiyo, Murotani Kenta, Nakayama Goro, Koike Masahiko, Ando Yuichi, Ebata Tomoki, Kodera Yasuhiro

    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS   24 巻   頁: 100853   2021年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:Contemporary Clinical Trials Communications  

    In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating resectable stage II or III esophageal squamous cell carcinoma (ESCC). However, 5-fluorouracil plus cisplatin does not benefit cohorts with clinical stage III ESCC, suggesting the requirement for a more effective regimen. We are conducting a single-arm phase II study to assess the safety and efficacy of neoadjuvant docetaxel, oxaliplatin plus S-1 (DOS) for treating patients with clinical stage III ESCC. The primary endpoint is the pathological response rate, and the target number is 45 patients. Safety, response rate, R0 resection rate, and survival are secondary endpoints. This trial is registered in the Japan Registry of Clinical Trials as jRCTs041210023. We are conducting a prospective phase II trial to evaluate the safety and efficacy of three courses of neoadjuvant DOS treatment followed by radical esophagectomy for clinical stage III ESCC.

    DOI: 10.1016/j.conctc.2021.100853

    Web of Science

    Scopus

    PubMed

  9. Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin

    Shimizu Dai, Taniue Kenzui, Matsui Yusuke, Haeno Hiroshi, Araki Hiromitsu, Miura Fumihito, Fukunaga Mitsuko, Shiraishi Kenji, Miyamoto Yuji, Tsukamoto Seiichi, Komine Aya, Kobayashi Yuta, Kitagawa Akihiro, Yoshikawa Yukihiro, Sato Kuniaki, Saito Tomoko, Ito Shuhei, Masuda Takaaki, Niida Atsushi, Suzuki Makoto, Baba Hideo, Ito Takashi, Akimitsu Nobuyoshi, Kodera Yasuhiro, Mimori Koshi

    CANCER GENE THERAPY     2021年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:Cancer Gene Therapy  

    The accurate and early diagnosis and classification of cancer origin from either tissue or liquid biopsy is crucial for selecting the appropriate treatment and reducing cancer-related mortality. Here, we established the CAncer Cell-of-Origin (CACO) methylation panel using the methylation data of the 28 types of cancer in The Cancer Genome Atlas (7950 patients and 707 normal controls) as well as healthy whole blood samples (95 subjects). We showed that the CACO methylation panel had high diagnostic potential with high sensitivity and specificity in the discovery (maximum AUC = 0.998) and validation (maximum AUC = 1.000) cohorts. Moreover, we confirmed that the CACO methylation panel could identify the cancer cell type of origin using the methylation profile from liquid as well as tissue biopsy, including primary, metastatic, and multiregional cancer samples and cancer of unknown primary, independent of the methylation analysis platform and specimen preparation method. Together, the CACO methylation panel can be a powerful tool for the classification and diagnosis of cancer.

    DOI: 10.1038/s41417-021-00401-w

    Web of Science

    Scopus

    PubMed

  10. E-PASS scoring system serves as a predictor of short- and long-term outcomes in gastric cancer surgery.

    Nakanishi K, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Kobayashi D, Shimizu D, Tanaka C, Fujiwara M, Murotani K, Kodera Y

    Surgery today     2021年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s00595-021-02394-3

    PubMed

  11. Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells

    Kanda Mitsuro, Shimizu Dai, Nakamura Shunsuke, Sawaki Koichi, Umeda Shinichi, Miwa Takashi, Tanaka Haruyoshi, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Nakayama Goro, Iguchi Yohei, Katsuno Masahisa, Kodera Yasuhiro

    ONCOGENE   40 巻 ( 36 ) 頁: 5495 - 5504   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:Oncogene  

    Here, we evaluated the therapeutic potential of antibodies (Abs) targeting cholinergic receptor nicotinic beta 2 subunit (CHRNB2) in gastric cancer. To investigate the effects of these Abs on malignant phenotypes in vitro and in mouse xenograft models, we generated gene knockouts through genome editing, performed RNA interference-mediated knockdown of gene expression, and ectopically expressed CHRNB2 in gastric cancer cells. The effects of anti-CHRNB2 Abs on the proliferation of cancer cells were evaluated both in vitro and in vivo. We determined the effects of Chrnb2 deficiency on mice and the clinical significance of CHRNB2 expression in gastric cancer clinical specimens. Knockdown of CHRNB2 attenuated gastric cancer cell proliferation, whereas forced overexpression of CHRNB2 increased cell proliferation. Knockout of CHRNB2 significantly influenced cell survival and functions associated with metastasis. The effects of polyclonal Abs targeting the C- and N-termini of CHRNB2 guided the development of anti-CHRNB2 monoclonal Abs that inhibited the growth of gastric cancer cells in vitro and in vivo. Pathway analysis revealed that CHRNB2 interfered with signaling through the PI3K-AKT and JAK-STAT pathways. Chrnb2-deficient mice exhibited normal reproduction, organ functions, and motor functions. CHRNB2 regulates multiple oncological phenotypes associated with metastasis, and blockade of CHRNB2 expression using specific Abs shows promise for controlling metastasis in gastric cancer.

    DOI: 10.1038/s41388-021-01945-9

    Web of Science

    Scopus

    PubMed

  12. Prognostic impact of a microscopic positive margin in patients undergoing gastrectomy for gastric cancer: a propensity score-matched analysis of a multi-institutional dataset

    Nakanishi Koki, Kanda Mitsuro, Ito Seiji, Mochizuki Yoshinari, Teramoto Hitoshi, Ishigure Kiyoshi, Murai Toshifumi, Asada Takahiro, Ishiyama Akiharu, Matsushita Hidenobu, Shimizu Dai, Tanaka Chie, Fujiwara Michitaka, Murotani Kenta, Kodera Yasuhiro

    SURGERY TODAY     2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:Surgery Today  

    Purpose: We analyzed the effect of a microscopic positive margin on survival outcomes after gastrectomy for gastric cancer Methods: We analyzed a multi-institutional dataset to study patients who underwent gastrectomy with curative intent between 2010 and 2014. We used propensity score matching to strictly balance the patients’ oncological features, backgrounds, and postoperative treatment to compare the survival outcomes of those with microscopic positive margins and those with negative margins. Results: Among 3029 patients, 32 (1.1%) had positive margins. After matching, we enrolled 128 patients in this retrospective analysis: 32 with a positive margin and 96 with a negative margin. The recurrence-free survival of the positive-margin group was significantly shorter than that of the negative-margin group (hazard ratio [HR], 1.62, 95% confidence interval, 1.00–2.63, p = 0.0485). Consistent results were observed for patients with pStages I–III disease (HR, 1.65, p = 0.0835), whereas the survival curves overlapped in those with pStage IV disease (HR, 1.29, p = 0.5934). The prevalence of overall recurrence in the positive-margin group was higher than that in the negative-margin group (75% vs 58%, p = 0.0917). This trend was consistent with locoregional recurrence (9% vs 3%) and distant recurrence (69% vs 55%). Conclusions: The survival of patients after curative gastrectomy for gastric cancer was worse in those with microscopic positive margins than in those with negative margins.

    DOI: 10.1007/s00595-021-02365-8

    Web of Science

    Scopus

    PubMed

  13. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.

    Yamanaka M, Hayashi M, Yamada S, Sonohara F, Takami H, Inokawa Y, Shimizu D, Hattori N, Kanda M, Tanaka C, Nakayama G, Koike M, Kodera Y

    Anticancer research   41 巻 ( 8 ) 頁: 3933 - 3940   2021年8月

     詳細を見る

    記述言語:英語   出版者・発行元:Anticancer Research  

    Background: Oligometastatic cancer (OM) is possibly associated with relatively better survival outcomes. We attempted to identify cases in line with this OM concept. Patients and Methods: A total of 130 cases with unresectable metastatic pancreatic cancer underwent non-curative surgery from April 2001 to December 2019. Sites of metastasis, clinicopathological information, and surgical outcomes were collected to formulate a better definition of OM. Results: OM criteria were defined as having metastasis to a single organ, few countable lesions and low serum cancer antigen 19-9 level. The median overall survival after non-curative surgery of OM cases was 13.0 months and was significantly better than that of non-OM cases (8.4 months, p=0.003). Conclusion: We propose single-organ metastasis of limited tumor volume (H1 or P1/2 by the Japanese Society of Cancer of the Colon and Rectum classification) and low serum cancer antigen 19-9 level (<2,000 U/ml) as new criteria for defining OM pancreatic cancer.

    DOI: 10.21873/anticanres.15189

    Scopus

    PubMed

  14. Mitotic checkpoint regulator RAE1 promotes tumor growth in colorectal cancer.

    Kobayashi Y, Masuda T, Fujii A, Shimizu D, Sato K, Kitagawa A, Tobo T, Ozato Y, Saito H, Kuramitsu S, Noda M, Otsu H, Mizushima T, Doki Y, Eguchi H, Mori M, Mimori K

    Cancer science     2021年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1111/cas.14969

    PubMed

  15. Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database

    Umeda Shinichi, Kanda Mitsuro, Nakanishi Koki, Ito Seiji, Mochizuki Yoshinari, Teramoto Hitoshi, Ishigure Kiyoshi, Murai Toshifumi, Asada Takahiro, Ishiyama Akiharu, Matsushita Hidenobu, Shimizu Dai, Kobayashi Daisuke, Tanaka Chie, Fujiwara Michitaka, Murotani Kenta, Kodera Yasuhiro

    SURGERY TODAY   51 巻 ( 5 ) 頁: 821 - 828   2021年5月

     詳細を見る

    出版者・発行元:Surgery Today  

    DOI: 10.1007/s00595-020-02179-0

    Web of Science

    Scopus

    PubMed

  16. Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53-Bcl-2 intrinsic apoptosis pathway

    Miwa Takashi, Kanda Mitsuro, Shimizu Dai, Umeda Shinichi, Sawaki Koichi, Tanaka Haruyoshi, Tanaka Chie, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Nakayama Goro, Koike Masahiko, Kodera Yasuhiro

    BRITISH JOURNAL OF CANCER   124 巻 ( 8 ) 頁: 1449 - 1460   2021年4月

     詳細を見る

    出版者・発行元:British Journal of Cancer  

    DOI: 10.1038/s41416-021-01271-7

    Web of Science

    Scopus

    PubMed

  17. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma

    Suenaga Masaya, Fujii Tsutomu, Yamada Suguru, Hayashi Masamichi, Shinjo Keiko, Takami Hideki, Niwa Yukiko, Sonohara Fuminori, Shimizu Dai, Kanda Mitsuro, Kobayashi Daisuke, Tanaka Chie, Nakayama Goro, Koike Masahiko, Fujiwara Michitaka, Kondo Yutaka, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY   28 巻 ( 4 ) 頁: 2277 - 2286   2021年4月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-020-08990-w

    Web of Science

    Scopus

    PubMed

  18. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer.

    Fujii A, Masuda T, Iwata M, Tobo T, Wakiyama H, Koike K, Kosai K, Nakano T, Kuramitsu S, Kitagawa A, Sato K, Kouyama Y, Shimizu D, Matsumoto Y, Utsunomiya T, Ohtsuka T, Yamanishi Y, Nakamura M, Mimori K

    Cancer science   112 巻 ( 4 ) 頁: 1655 - 1668   2021年4月

     詳細を見る

  19. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer

    Shibata Masahiro, Inaishi Takahiro, Ichikawa Takahiro, Shimizu Dai, Soeda Ikumi, Takano Yuko, Takeuchi Dai, Tsunoda Nobuyuki, Kikumori Toyone

    SURGERY TODAY     2021年3月

     詳細を見る

    出版者・発行元:Surgery Today  

    DOI: 10.1007/s00595-021-02262-0

    Web of Science

    Scopus

    PubMed

  20. Function and prognostic value of melanoma-associated antigen-D4 protein in esophageal squamous cell carcinoma

    Sawaki Koichi, Kanda Mitsuro, Sato Yusuke, Shimizu Dai, Uno Yasuo, Umeda Shinichi, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Yamada Suguru, Nakayama Goro, Motoyama Satoru, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    CANCER SCIENCE   112 巻   頁: 531 - 531   2021年2月

     詳細を見る

  21. STRA6 expression serves as a prognostic biomarker of gastric cancer

    Nakamura Shunsuke, Kanda Mitsuro, Shimizu Dai, Sawaki Koichi, Tanaka Chie, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Koike Masahiko, Kodera Yasuhiro

    CANCER SCIENCE   112 巻   頁: 780 - 780   2021年2月

     詳細を見る

  22. Tissue RNFT2 Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer

    Sasahara Masahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Chie, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Nakayama Goro, Kodera Yasuhiro

    ANTICANCER RESEARCH   41 巻 ( 2 ) 頁: 609 - 617   2021年2月

  23. Tissue RNFT2 Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer

    Sasahara Masahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Chie, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Nakayama Goro, Kodera Yasuhiro

    ANTICANCER RESEARCH   41 巻 ( 2 ) 頁: 609 - 617   2021年2月

  24. Tissue RNFT2 expression levels are associated with peritoneal recurrence and poor prognosis in gastric cancer

    Sasahara M.

    Anticancer Research   41 巻 ( 2 ) 頁: 609 - 617   2021年2月

     詳細を見る

    出版者・発行元:Anticancer Research  

    DOI: 10.21873/ANTICANRES.14812

    Scopus

  25. Tissue <i>RNFT2</i> Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer.

    Sasahara M, Kanda M, Shimizu D, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Nakayama G, Kodera Y

    Anticancer research   41 巻 ( 2 ) 頁: 609 - 617   2021年2月

     詳細を見る

  26. Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases.

    Sakimura S, Nagayama S, Fukunaga M, Hu Q, Kitagawa A, Kobayashi Y, Hasegawa T, Noda M, Kouyama Y, Shimizu D, Saito T, Niida A, Tsuruda Y, Otsu H, Matsumoto Y, Uchida H, Masuda T, Sugimachi K, Sasaki S, Yamada K, Takahashi K, Innan H, Suzuki Y, Nakamura H, Totoki Y, Mizuno S, Ohshima M, Shibata T, Mimori K

    PLoS genetics   17 巻 ( 1 ) 頁: e1009113   2021年1月

  27. Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus

    Shimizu Dai, Koike Masahiko, Kanda Mitsuro, Sonohara Fuminori, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Yamada Suguru, Kodera Yasuhiro

    SURGERY TODAY   51 巻 ( 1 ) 頁: 153 - 158   2021年1月

     詳細を見る

    出版者・発行元:Surgery Today  

    DOI: 10.1007/s00595-020-02072-w

    Web of Science

    Scopus

    PubMed

  28. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy

    Sonohara Fuminori, Yamada Suguru, Kurimoto Keisuke, Inokawa Yoshikuni, Takami Hideki, Hayashi Masamichi, Shimizu Dai, Hattori Norifumi, Kanda Mitsuro, Tanaka Chie, Nakayama Goro, Koike Masahiko, Fujii Tsutomu, Kodera Yasuhiro

    PANCREAS   50 巻 ( 1 ) 頁: 37 - 46   2021年1月

     詳細を見る

  29. Different Characteristics of Serum Alfa Fetoprotein and Serum Des-gamma-carboxy Prothrombin in Resected Hepatocellular Carcinoma

    Hayashi Masamichi, Yamada Suguru, Takano Nao, Okamura Yukiyasu, Takami Hideki, Inokawa Yoshikuni, Sonohara Fuminori, Tanaka Nobutake, Shimizu Dai, Hattori Norifumi, Kanda Mitsuro, Tanaka Chie, Nakayama Goro, Koike Masahiko, Kodera Yasuhiro

    IN VIVO   35 巻 ( 3 ) 頁: 1749 - 1760   2021年

     詳細を見る

    記述言語:日本語   出版者・発行元:In Vivo  

    DOI: 10.21873/invivo.12434

    Web of Science

    Scopus

    PubMed

  30. Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer

    Kanda Mitsuro, Kasahara Yuuya, Shimizu Dai, Miwa Takashi, Umeda Shinichi, Sawaki Koichi, Nakamura Shunsuke, Kodera Yasuhiro, Obika Satoshi

    MOLECULAR THERAPY-NUCLEIC ACIDS   22 巻   頁: 791 - 802   2020年12月

     詳細を見る

    出版者・発行元:Molecular Therapy - Nucleic Acids  

    DOI: 10.1016/j.omtn.2020.10.001

    Web of Science

    Scopus

    PubMed

  31. AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer

    Nakamura Shunsuke, Kanda Mitsuro, Shimizu Dai, Tanaka Chie, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Nakayama Goro, Omae Kenji, Koike Masahiko, Kodera Yasuhiro

    ANTICANCER RESEARCH   40 巻 ( 12 ) 頁: 6713 - 6721   2020年12月

     詳細を見る

    出版者・発行元:Anticancer Research  

    DOI: 10.21873/anticanres.14694

    Web of Science

    Scopus

    PubMed

  32. AnOpen-Label Single-ArmPhaseIIStudy of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical StageIIISquamous Cell Carcinoma of the Esophagus

    Kanda Mitsuro, Koike Masahiko, Iwata Naoki, Shimizu Dai, Tanaka Chie, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Omae Kenji, Nakayama Goro, Kodera Yasuhiro

    ONCOLOGIST   25 巻 ( 11 ) 頁: E1650 - E1654   2020年11月

     詳細を見る

  33. Characteristics Associated with Nodal and Distant Recurrence after Curative Resection of Squamous Cell Carcinoma of the Thoracic Esophagus

    Kanda Mitsuro, Koike Masahiko, Shimizu Dai, Tanaka Chie, Hayashi Masamichi, Hattori Norifumi, Yamada Suguru, Nakayama Goro, Fujiwara Michitaka, Kodera Yasuhiro

    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS   231 巻 ( 4 ) 頁: E121 - E121   2020年10月

     詳細を見る

  34. Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients.

    Noda M, Masuda T, Ito S, Tobo T, Kitagawa A, Hu Q, Shimizu D, Eguchi H, Etoh T, Ohno S, Inomata M, Mimori K

    Annals of surgical oncology   27 巻 ( 10 ) 頁: 4035 - 4043   2020年10月

     詳細を見る

  35. Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus

    Kanda Mitsuro, Koike Masahiko, Shimizu Dai, Tanaka Chie, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Omae Kenji, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY   27 巻 ( 9 ) 頁: 3195 - 3205   2020年9月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-020-08433-6

    Web of Science

    Scopus

    PubMed

  36. Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma

    Baba Hayato, Kanda Mitsuro, Sato Yusuke, Sawaki Koichi, Shimizu Dai, Koike Masahiko, Motoyama Satoru, Kodera Yasuhiro, Fujii Tsutomu

    ANNALS OF SURGICAL ONCOLOGY   27 巻 ( 9 ) 頁: 3247 - 3256   2020年9月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-020-08431-8

    Web of Science

    Scopus

    PubMed

  37. Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer

    Kanda Mitsuro, Shimizu Dai, Sawaki Koichi, Nakamura Shunsuke, Umeda Shinichi, Miwa Takashi, Tanaka Haruyoshi, Tanaka Chie, Hayashi Masamichi, Iguchi Yohei, Yamada Suguru, Katsuno Masahisa, Kodera Yasuhiro

    MOLECULAR CANCER   19 巻 ( 1 ) 頁: 131   2020年8月

     詳細を見る

    出版者・発行元:Molecular Cancer  

    DOI: 10.1186/s12943-020-01251-0

    Web of Science

    Scopus

    PubMed

  38. 特集 解剖学的変異を考慮した上部消化管手術 局所微細解剖からみた幽門下リンパ節郭清のコツ─腹腔鏡手術を中心に

    田中 千恵, 佐藤 敏, 神田 光郎, 清水 大, 小寺 泰弘

    手術   74 巻 ( 9 ) 頁: 1339 - 1346   2020年8月

     詳細を見る

    出版者・発行元:金原出版  

    DOI: 10.18888/op.0000001828

    CiNii Research

  39. Diagnostic and therapeutic role of endoscopic retrograde pancreatography and stent placement for grade IV blunt pancreatic trauma: A case report.

    Shimizu D, Yamano T, Kudo Y, Kuroda M, Takagi S, Ikeda E, Kenmotsu M, Tsuji H

    Trauma case reports   28 巻   頁: 100319   2020年8月

     詳細を見る

  40. KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma

    Nakamura Shunsuke, Kanda Mitsuro, Koike Masahiko, Shimizu Dai, Umeda Shinichi, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Kobayashi Daisuke, Yamada Suguru, Omae Kenji, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY   27 巻 ( 7 ) 頁: 2559 - 2568   2020年7月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-019-08189-8

    Web of Science

    Scopus

    PubMed

  41. Propensity-score-matched analysis of a multi-institutional dataset to compare postoperative complications between Billroth I and Roux-en-Y reconstructions after distal gastrectomy

    Nakanishi Koki, Kanda Mitsuro, Ito Seiji, Mochizuki Yoshinari, Teramoto Hitoshi, Ishigure Kiyoshi, Murai Toshifumi, Asada Takahiro, Ishiyama Akiharu, Matsushita Hidenobu, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Fujiwara Michitaka, Murotani Kenta, Kodera Yasuhiro

    GASTRIC CANCER   23 巻 ( 4 ) 頁: 734 - 745   2020年7月

     詳細を見る

    出版者・発行元:Gastric Cancer  

    DOI: 10.1007/s10120-020-01048-6

    Web of Science

    Scopus

    PubMed

  42. High Serum Uric Acid Levels Could Be a Risk Factor of Hepatocellular Carcinoma Recurrences

    Hayashi Masamichi, Yamada Suguru, Tanabe Hiroshi, Takami Hideki, Inokawa Yoshikuni, Sonohara Fuminori, Shimizu Dai, Hattori Norifumi, Kanda Mitsuro, Tanaka Chie, Nakayama Goro, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL     頁: 1 - 8   2020年6月

     詳細を見る

    出版者・発行元:Nutrition and Cancer  

    DOI: 10.1080/01635581.2020.1779758

    Web of Science

    Scopus

    PubMed

  43. PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer

    Baba Hayato, Kanda Mitsuro, Sawaki Koichi, Umeda Shinichi, Miwa Takashi, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Fujiwara Michitaka, Kodera Yasuhiro, Fujii Tsutomu

    ANNALS OF SURGICAL ONCOLOGY   27 巻 ( 6 ) 頁: 2071 - 2080   2020年6月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-019-07985-6

    Web of Science

    Scopus

    PubMed

  44. Optimized Cutoff Value of Serum Squamous Cell Carcinoma Antigen Concentration Accurately Predicts Recurrence After Curative Resection of Squamous Cell Carcinoma of the Esophagus

    Kanda Mitsuro, Koike Masahiko, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Hattori Norifumi, Hayashi Masamichi, Omae Kenji, Yamada Suguru, Nakayama Goro, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY   27 巻 ( 4 ) 頁: 1233 - 1240   2020年4月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-019-07977-6

    Web of Science

    Scopus

    PubMed

  45. KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma.

    Kitagawa A, Masuda T, Takahashi J, Tobo T, Noda M, Kuroda Y, Hu Q, Kouyama Y, Kobayashi Y, Kuramitsu S, Sato K, Fujii A, Yoshikawa Y, Wakiyama H, Shimizu D, Tsuruda Y, Eguchi H, Doki Y, Mori M, Mimori K

    Cancer genomics & proteomics   17 巻 ( 2 ) 頁: 141 - 149   2020年3月

     詳細を見る

  46. Predictive value of the modified systemic inflammation score in patients undergoing curative resection of squamous cell carcinoma of the esophagus

    Kanda Mitsuro, Koike Masahiko, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Sonohara Fuminori, Takami Hideki, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Nakayama Goro, Fujiwara Michitaka, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   38 巻 ( 4 )   2020年2月

     詳細を見る

  47. Propensity-score-matched analysis of a multi-institutional dataset to compare the postoperative complications after distal gastrectomy between Billroth I and Roux-en-Y

    Nakanishi Koki, Kanda Mitsuro, Ito Seiji, Mochizuki Yoshinari, Teramoto Hitoshi, Ishigure Kiyoshi, Mmurai Toshifumi, Asada Takahiro, Ishiyama Akiharu, Matsushita Hidenobu, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Fujiwara Michitaka, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   38 巻 ( 4 )   2020年2月

     詳細を見る

  48. Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma

    Ueda Sei, Kanda Mitsuro, Sato Yusuke, Baba Hayato, Nakamura Shunsuke, Sawaki Koichi, Shimizu Dai, Motoyama Satoru, Fujii Tsutomu, Kodera Yasuhiro, Nomoto Shuji

    CANCER GENOMICS & PROTEOMICS   17 巻 ( 4 ) 頁: 391 - 400   2020年

     詳細を見る

    出版者・発行元:Cancer Genomics and Proteomics  

    DOI: 10.21873/cgp.20198

    Web of Science

    Scopus

    PubMed

  49. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.

    Ito S, Masuda T, Noda M, Hu Q, Shimizu D, Kuroda Y, Eguchi H, Tobo T, Utsunomiya T, Mimori K

    Oncology   98 巻 ( 7 ) 頁: 501 - 511   2020年

     詳細を見る

  50. 食道癌術後の心房細動発症が術後経過、身体機能に及ぼす影響

    白井 祐也, 水野 陽太, 清水 大, 井上 貴行, 岡田 貴士, 西田 佳弘, 小池 聖彦, 永谷 元基

    理学療法学Supplement   47 巻 ( 0 ) 頁: C - 17_2-C-17_2   2020年

     詳細を見る

    出版者・発行元:公益社団法人 日本理学療法士協会  

    DOI: 10.14900/cjpt.47S1.C-17_2

  51. STRA6 Expression Serves as a Prognostic Biomarker of Gastric Cancer

    Nakamura Shunsuke, Kanda Mitsuro, Shimizu Dai, Sawaki Kouichi, Tanaka Chie, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Nakayama Goro, Omae Kenji, Koike Masahiko, Kodera Yasuhiro

    CANCER GENOMICS & PROTEOMICS   17 巻 ( 5 ) 頁: 509 - 516   2020年

     詳細を見る

    出版者・発行元:Cancer Genomics and Proteomics  

    DOI: 10.21873/cgp.20207

    Web of Science

    Scopus

    PubMed

  52. Salivary NUS1 and RCN1 Levels as Biomarkers for Oral Squamous Cell Carcinoma Diagnosis

    Ueda Sei, Hashimoto Kengo, Miyabe Satoru, Hasegawa Shogo, Goto Mitsuo, Shimizu Dai, Oh-Iwa Ichiro, Shimozato Kazuo, Nagao Toru, Nomoto Shuji

    IN VIVO   34 巻 ( 5 ) 頁: 2353 - 2361   2020年

     詳細を見る

    出版者・発行元:In Vivo  

    DOI: 10.21873/invivo.12048

    Web of Science

    Scopus

    PubMed

  53. Changes in oral microbial profiles associated with oral squamous cell carcinoma vs leukoplakia.

    Hashimoto K, Shimizu D, Hirabayashi S, Ueda S, Miyabe S, Oh-Iwa I, Nagao T, Shimozato K, Nomoto S

    Journal of investigative and clinical dentistry   10 巻 ( 4 ) 頁: e12445   2019年11月

     詳細を見る

    出版者・発行元:Journal of investigative and clinical dentistry  

    DOI: 10.1111/jicd.12445

    Scopus

    PubMed

  54. Expression, Function, and Prognostic Value of MAGE-D4 Protein in Esophageal Squamous Cell Carcinoma

    Uno Yasuo, Kanda Mitsuro, Sato Yusuke, Shimizu Dai, Umeda Shinichi, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Kobayashi Daisuke, Yamada Suguru, Nakayama Goro, Motoyama Satoru, Koike Masahiko, Kodera Yasuhiro

    ANTICANCER RESEARCH   39 巻 ( 11 ) 頁: 6015 - 6023   2019年11月

     詳細を見る

    出版者・発行元:Anticancer Research  

    DOI: 10.21873/anticanres.13807

    Web of Science

    Scopus

    PubMed

  55. PRAME Expression as a Potential Biomarker for Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma

    Baba Hayato, Kanda Mitsuro, Sawaki Koichi, Shimizu Dai, Umeda Shinichi, Koike Masahiko, Kodera Yasuhiro, Fujii Tsutomu

    ANTICANCER RESEARCH   39 巻 ( 11 ) 頁: 5943 - 5951   2019年11月

     詳細を見る

    出版者・発行元:Anticancer Research  

    DOI: 10.21873/anticanres.13799

    Web of Science

    Scopus

    PubMed

  56. Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer

    Endo Miyo, Kanda Mitsuro, Sawaki Koichi, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Hattori Norifumi, Hayashi Masamichi, Yamada Suguru, Koike Masahiko, Omae Kenji, Kodera Yasuhiro

    ANTICANCER RESEARCH   39 巻 ( 11 ) 頁: 5903 - 5910   2019年11月

     詳細を見る

    出版者・発行元:Anticancer Research  

    DOI: 10.21873/anticanres.13794

    Web of Science

    Scopus

    PubMed

  57. CRMP5-associated GTPase (CRAG) Is a Candidate Driver Gene for Colorectal Cancer Carcinogenesis

    Shimizu Dai, Masuda Takaaki, Sato Kuniaki, Tsuruda Yusuke, Otsu Hajime, Kuroda Yosuke, Eguchi Hidetoshi, Kodera Yasuhiro, Mimori Koshi

    ANTICANCER RESEARCH   39 巻 ( 1 ) 頁: 99 - 106   2019年1月

     詳細を見る

    出版者・発行元:Anticancer Research  

    DOI: 10.21873/anticanres.13084

    Web of Science

    Scopus

    PubMed

  58. Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors.

    Sato K, Niida A, Masuda T, Shimizu D, Tobo T, Kuroda Y, Eguchi H, Nakagawa T, Suzuki Y, Mimori K

    Cancer genomics & proteomics   16 巻 ( 1 ) 頁: 21 - 27   2019年1月

     詳細を見る

  59. Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines

    Miwa Takashi, Kanda Mitsuro, Umeda Shinichi, Tanaka Haruyoshi, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Hayashi Masamichi, Yamada Suguru, Nakayama Goro, Koike Masahiko, Kodera Yasuhiro

    IN VIVO   33 巻 ( 6 ) 頁: 1785 - 1792   2019年

     詳細を見る

    出版者・発行元:In Vivo  

    DOI: 10.21873/invivo.11669

    Web of Science

    Scopus

    PubMed

  60. A case of renal salt-wasting syndrome induced by cisplatin and 5-FU during treatment of esophageal squamous cell carcinoma

    Shimizu D.

    Annals of Cancer Research and Therapy   27 巻 ( 2 ) 頁: 64 - 66   2019年

     詳細を見る

    出版者・発行元:Annals of Cancer Research and Therapy  

    <p>The combination regimen of cisplatin (CDDP) and fluorouracil (5-FU) (FP) is a standard regimen for definitive chemoradiotherapy, neoadjuvant chemotherapy, and for treatment of unresectable or recurrent esophageal squamous cell carcinoma (ESCC). Here, we report a patient with FP-induced renal salt-wasting syndrome (RSWS) who presented with severe hyponatremia with disturbance of consciousness and was admitted to the intensive care unit (ICU). A 66-year-old man with recurrent ESCC was admitted and started on chemotherapy with FP. From day 3 of the first course of FP, he presented with anorexia and vomiting (grade 3). At day 6, he experienced disturbance of consciousness and blood test showed severe hyponatremia (sodium (Na): 119 mmol/L) accompanied with excessive urinary excretion of Na (181 mmol/L). He was diagnosed with RSWS because of CDDP and was transferred to the ICU. Through intensive monitoring and 3% NaCl infusion, serum Na level and symptoms recovered with no sequelae and he was discharged from the ICU after a 4-day stay.</p><p>RSWS is sometimes difficult to diagnose because of its low recognition and is misdiagnosed as the syndrome of inappropriate secretion of antidiuretic hormone. During chemotherapy with platinum-based agents, RSWS should be kept in mind as a disorder that causes hyponatremia.</p>

    DOI: 10.4993/acrt.27.64

    Scopus

  61. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma

    Suenaga M., Fujii T., Yamada S., Hayashi M., Shinjo K., Takami H., Niwa Y., Sonohara F., Shimizu D., Kanda M., Kobayashi D., Tanaka C., Nakayama G., Koike M., Fujiwara M., Kondo Y., Kodera Y.

    PANCREAS   48 巻 ( 10 ) 頁: 1528 - 1528   2019年

     詳細を見る

  62. Biological significance of ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 (AGAP3) in colorectal cancer (CRC)

    Shimizu Dai, Sato Kuniaki, Masuda Takaaki, Otsu Hajime, Kuroda Yousuke, Eguchi Hidetoshi, Kanda Mitsuro, Kodera Yasuhiro, Mimori Koshi

    CANCER SCIENCE   109 巻   頁: 1235 - 1235   2018年12月

     詳細を見る

  63. RASEF expression correlates with hormone receptor status in breast cancer

    Shibata Masahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Haruyoshi, Umeda Shinichi, Miwa Takashi, Hayashi Masamichi, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY LETTERS   16 巻 ( 6 ) 頁: 7223 - 7230   2018年12月

     詳細を見る

    出版者・発行元:Oncology Letters  

    DOI: 10.3892/ol.2018.9542

    Web of Science

    Scopus

    PubMed

  64. Cutting-edge evidence of adjuvant treatments for gastric cancer

    Shimizu Dai, Kanda Mitsuro, Kodera Yasuhiro, Sakamoto Junichi

    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY   12 巻 ( 11 ) 頁: 1109 - 1122   2018年11月

     詳細を見る

    出版者・発行元:Expert Review of Gastroenterology and Hepatology  

    DOI: 10.1080/17474124.2018.1530985

    Web of Science

    Scopus

    PubMed

  65. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.

    Ito S, Fukagawa T, Noda M, Hu Q, Nambara S, Shimizu D, Kuroda Y, Eguchi H, Masuda T, Sato T, Katai H, Sasako M, Mimori K

    Annals of surgical oncology   25 巻 ( 12 ) 頁: 3755 - 3763   2018年11月

     詳細を見る

  66. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells

    Kanda Mitsuro, Tanaka Haruyoshi, Shimizu Dai, Miwa Takashi, Umeda Shinichi, Tanaka Chie, Kobayashi Daisuke, Hattori Norifumi, Suenaga Masaya, Hayashi Masamichi, Iwata Naoki, Yamada Suguru, Fujiwara Michitaka, Kodera Yasuhiro

    ONCOGENE   37 巻 ( 39 ) 頁: 5355 - 5366   2018年9月

     詳細を見る

    出版者・発行元:Oncogene  

    DOI: 10.1038/s41388-018-0335-8

    Web of Science

    Scopus

    PubMed

  67. Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer

    Kanda M., Shimizu D., Tanaka H., Tanaka C., Kobayashi D., Hayashi M., Takami H., Niwa Y., Yamada S., Fujii T., Sugimoto H., Kodera Y.

    BRITISH JOURNAL OF SURGERY   105 巻 ( 10 ) 頁: 1349 - 1358   2018年9月

     詳細を見る

    出版者・発行元:British Journal of Surgery  

    DOI: 10.1002/bjs.10876

    Web of Science

    Scopus

  68. Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer

    Shimizu Dai, Kanda Mitsuro, Kodera Yasuhiro

    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY   10 巻 ( 6 ) 頁: 124 - 136   2018年6月

     詳細を見る

    出版者・発行元:World Journal of Gastrointestinal Oncology  

    DOI: 10.4251/wjgo.v10.i6.124

    Web of Science

    Scopus

    PubMed

  69. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer

    Kanda Mitsuro, Shimizu Dai, Tanaka Haruyoshi, Tanaka Chie, Kobayashi Daisuke, Hayashi Masamichi, Iwata Naoki, Niwa Yukiko, Yamada Suguru, Fujii Tsutomu, Sugimoto Hiroyuki, Murotani Kenta, Fujiwara Michitaka, Kodera Yasuhiro

    ANNALS OF SURGERY   267 巻 ( 3 ) 頁: 495 - 503   2018年3月

     詳細を見る

    出版者・発行元:Annals of Surgery  

    DOI: 10.1097/SLA.0000000000002096

    Web of Science

    Scopus

    PubMed

  70. Review of recent molecular landscape knowledge of gastric cancer

    Shimizu Dai, Kanda Mitsuro, Kodera Yasuhiro

    HISTOLOGY AND HISTOPATHOLOGY   33 巻 ( 1 ) 頁: 11 - 26   2018年1月

     詳細を見る

    出版者・発行元:Histology and Histopathology  

    DOI: 10.14670/HH-11-898

    Web of Science

    Scopus

    PubMed

  71. Overexpression of FGFR1 Promotes Peritoneal Dissemination Via Epithelial-to-Mesenchymal Transition in Gastric Cancer

    Shimizu Dai, Saito Tomoko, Ito Shuhei, Masuda Takaaki, Kurashige Junji, Kuroda Yosuke, Eguchi Hidetoshi, Kodera Yasuhiro, Mimori Koshi

    CANCER GENOMICS & PROTEOMICS   15 巻 ( 4 ) 頁: 313 - 320   2018年

     詳細を見る

    出版者・発行元:Cancer Genomics and Proteomics  

    DOI: 10.21873/cgp.20089

    Web of Science

    Scopus

    PubMed

  72. FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer

    Tanaka Haruyoshi, Kanda Mitsuro, Shimizu Dai, Tanaka Chie, Kobayashi Daisuke, Hayashi Masamichi, Iwata Naoki, Yamada Suguru, Fujii Tsutomu, Nakayama Goro, Sugimoto Hiroyuki, Fujiwara Michitaka, Niwa Yukiko, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY   24 巻 ( 11 ) 頁: 3438 - 3445   2017年10月

     詳細を見る

    出版者・発行元:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-016-5636-y

    Web of Science

    Scopus

    PubMed

  73. Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells

    Shibata Masahiro, Kanda Mitsuro, Tanaka Haruyoshi, Umeda Shinichi, Miwa Takashi, Shimizu Dai, Hayashi Masamichi, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY REPORTS   38 巻 ( 3 ) 頁: 1760 - 1766   2017年9月

     詳細を見る

    出版者・発行元:Oncology Reports  

    DOI: 10.3892/or.2017.5800

    Web of Science

    Scopus

    PubMed

  74. Expression of regulatory factor X1 can predict the prognosis of breast cancer

    Shibata Masahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Haruyoshi, Umeda Shinichi, Hayashi Masamichi, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY LETTERS   13 巻 ( 6 ) 頁: 4334 - 4340   2017年6月

     詳細を見る

    出版者・発行元:Oncology Letters  

    DOI: 10.3892/ol.2017.6005

    Web of Science

    Scopus

    PubMed

  75. Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review).

    Shimizu D, Inokawa Y, Sonohara F, Inaoka K, Nomoto S

    Oncology reports   37 巻 ( 5 ) 頁: 2527 - 2542   2017年5月

     詳細を見る

  76. GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer

    Shimizu Dai, Kanda Mitsuro, Tanaka Haruyoshi, Kobayashi Daisuke, Tanaka Chie, Hayashi Masamichi, Iwata Naoki, Niwa Yukiko, Takami Hideki, Yamada Suguru, Fujii Tsutomu, Nakayama Goro, Fujiwara Michitaka, Kodera Yasuhiro

    SCIENTIFIC REPORTS   7 巻   頁: 42089   2017年2月

     詳細を見る

    出版者・発行元:Scientific Reports  

    DOI: 10.1038/srep42089

    Web of Science

    Scopus

    PubMed

  77. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy

    Shimizu Dai, Kanda Mitsuro, Sugimoto Hiroyuki, Shibata Masahiro, Tanaka Haruyoshi, Takami Hideki, Iwata Naoki, Hayashi Masamichi, Tanaka Chie, Kobayashi Daisuke, Yamada Suguru, Nakayama Goro, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Kodera Yasuhiro

    INTERNATIONAL JOURNAL OF ONCOLOGY   50 巻 ( 2 ) 頁: 381 - 386   2017年2月

     詳細を見る

    出版者・発行元:International Journal of Oncology  

    DOI: 10.3892/ijo.2017.3833

    Web of Science

    Scopus

    PubMed

▼全件表示

科研費 7

  1. 臓器嗜好性に焦点をあてた食道癌転移の分子機序解明からの創薬研究

    研究課題/研究課題番号:21K19525  2021年7月 - 2024年3月

    科学研究費助成事業  挑戦的研究(萌芽)

    小寺 泰弘, 神田 光郎, 田中 千恵, 清水 大

      詳細を見る

    担当区分:研究分担者 

    食道癌転移経路特異的Transcriptome解析により、申請者らの仮説に一致して血行性転移群とリンパ行性転移で発現パターンが明瞭に異なるクラスターがあることが示され、血行性転移関連5分子(VWA5B2、CFAP47、NECAB2、SYCE3、RPL3L)、リンパ行性転移関連3分子(C1QL4、CCDC87、CAMK2N2)を厳選している。
    これらの食道癌転移形式別関連分子の機能解析・発現解析を行うことで、食道癌転移の分子生物学的機序の解明を通じ、食道癌予後を劇的に改善しうる分子標的治療薬と、その奏効度を事前に予測しうるコンパニオン診断法開発の基盤となるデータを得ることを目的とする。

  2. 細胞接着因子を標的とするデュアル修飾型アンチセンス核酸を用いた革新的癌治療薬創出

    研究課題/研究課題番号:21H02984  2021年4月 - 2025年3月

    科学研究費助成事業  基盤研究(B)

    小寺 泰弘, 神田 光郎, 笠原 勇矢, 田中 千恵, 清水 大, 小比賀 聡

      詳細を見る

    担当区分:研究分担者 

    本研究では、細胞接着因子を標的としたアンチセンス核酸医薬による新たな胃癌分子標的治療薬およびコンパニオン診断技術開発を目指して、以下を実施する。
    1) アンチセンス核酸スクリーニング、2) メカニズム解明(機能解析、シグナル解析、KOマウス解析、正常組織中発現解析)、3) in vitro活性評価(濃度依存性の活性、癌種横断的活性評価)、4) in vivo活性評価(皮下腫瘍モデル、同所移植モデルでの薬効評価)、5) 毒性評価とオフターゲット探索、6) コンパニオン診断(治療前生検、手術検体での免疫染色法による発現解析)

  3. DNAメチル化パネルによる多癌種鑑別診断技術の確立

    研究課題/研究課題番号:21K07240  2021年4月 - 2024年3月

    清水 大

      詳細を見る

    担当区分:研究代表者 

    配分額:4030000円 ( 直接経費:3100000円 、 間接経費:930000円 )

  4. 高機能性人工核酸を用いたアンチセンス核酸医薬による革新的消化器系癌創薬研究

    研究課題/研究課題番号:20K21629  2020年7月 - 2022年3月

    挑戦的研究(萌芽)

    神田 光郎

      詳細を見る

    担当区分:研究分担者 

    早期根治切除例の予後は期待できるものの、転移・再発性となるときわめて予後不良であることは、全ての消化器癌における共通かつ重大な問題点である。全身化学療法は分子標的治療薬を中心に徐々にラインナップを増やしているが、不応・耐性が治療成績の限界を産んでおり、全く別の作用機序を有するアプローチの開発が必要である。本研究では、新規標的分子に対する優れた阻害効果を有するアンチセンス核酸を創製し、革新的な効果を発揮する癌治療核酸医薬を開発していく。

  5. CHRNB2を標的とした革新的がん抗体医薬とコンパニオン診断技術の創出研究

    研究課題/研究課題番号:20H03750  2020年4月 - 2024年3月

    神田 光郎

      詳細を見る

    担当区分:研究分担者 

    CHRNB2を標的とした抗体医薬創薬ならびに治療奏効度を予測するコンパニオン診断技術の開発を目的として、以下の実験を行う。
    Ⅰ. メカニズム解明:KOマウス解析、機能解析、シグナル解析、正常組織中発現解析
    Ⅱ. ヒト化抗CHRNB2抗体:抗体合成、薬効評価
    Ⅲ. 抗体のprofiling:アフィニティ測定、エピトープマッピング
    Ⅳ. 抗体-化合物複合体:化合物スクリーニング、複合体合成、薬効評価
    Ⅴ. コンパニオン診断:臨床検体でのCHRNB2発現解析、臨床病理学的因子との相関解析

  6. cfDNAを用いた大腸癌特異的メチル化マーカーによる大腸癌存在診断法の開発

    研究課題/研究課題番号:19K16868  2019年4月 - 2021年3月

    若手研究

    清水 大

      詳細を見る

    担当区分:研究代表者 

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    体細胞変異に比べて一般に症例間や腫瘍内での不均一性が少ないDNAメチル化異常を標的として癌の存在診断を行う。Public databaseを用い、32種類という多癌腫間での比較から大腸癌特異的なメチル化異常部位を抽出し、ctDNA解析に応用する。すなわち、採血のみで他癌腫を鑑別し、大腸癌原発巣および転移巣の早期発見を可能とする技術開発を目指す。また、本アプローチは他癌腫にも応用可能であることから、各癌腫特異的なメチル化異常部位を標的として、採血のみで癌腫診断を可能にする検診技術の確立への発展性を有する研究である。

  7. FRAS1 を標的とした胃癌肝転移特異的な治療・診断法の開発

    研究課題/研究課題番号:17K16521  2017年4月 - 2019年3月

    清水 大

      詳細を見る

    担当区分:研究代表者 

    配分額:4030000円 ( 直接経費:3100000円 、 間接経費:930000円 )

    我々は、肝転移を有する胃癌患者の原発巣で有意に発現が上昇している遺伝子群をRNA sequencingの結果から抽出し、その遺伝子群からFRAS1を胃癌肝転移関連分子として着目した。CRISPR-Cas9システムを用いてFRAS1のノックアウト株を作成し、FRAS1ノックアウトに伴い増殖能・接着能・遊走能・浸潤能が有意に低下することを示した。また、FRAS1高発現症例は有意に累積肝転移発生率が高かった。マウス肝転移モデルをを用いて、FRAS1が転移巣形成においてより肝転移巣形成に重要な役割を果たしている事を示した。
    胃癌肝転移は有効な根治治療が確立されておらず致死的な病態である。胃癌が肝転移をきたすメカニズムや、肝転移を誘導する分子の解明は、胃癌の肝転移予測ならびに治療法の開発に不可欠である。今回我々はFRAS1を胃癌肝転移関連分子として同定し、その遺伝子発現が胃癌細胞の悪性度に関与することを明らかにした。また、胃癌患者コホートにおいてFRAS1発現は独立した肝転移予測因子であった。さらに動物実験では、FRAS1発現が肝転移に特徴的に関与する可能性を示した。今後、FRAS1が胃癌肝転移の予測マーカーならびに治療標的となる事が期待される。

▼全件表示